جستجوی استاد راهنمای دانشگاهی

Mark Crabtree is a University Research Lecturer and British Heart Foundation Intermediate Basic Science Research Fellow at the University of Oxford, leading the Channon Group focused on cardiovascular functional genomics and redox signaling. His research integrates metabolomic and proteomic approaches to study nitric oxide mechanisms in cardiovascular disease models. Education: BSc (Hons) from the University of Surrey (2001), followed by a collaborative PhD at the University of Surrey and Weill Medical College of Cornell University. Postdoctoral training under Professor Keith Channon began in 2006, supported by a BHF Centre of Research Excellence Transition Fellowship (2012–2015). Research interests include nitric oxide delivery systems for cardiovascular therapies, redox signaling in cardiac injury, and tetrahydrobiopterin's role in metabolic regulation. His work bridges nanomaterials development (e.g., graphene-based NO-releasing coatings) with clinical applications in ischemia-reperfusion injury and atherosclerosis. Notable contributions include advancements in pH-sensitive NO delivery systems and mechanistic insights into myocardial nitroso-redox imbalance post-cardiac surgery. He chairs the 2018 International Nitric Oxide Society Conference and serves on the society's council. Scientific awards: British Heart Foundation Intermediate Basic Science Research Fellowship. Active grants include BHF funding for redox signaling studies. His lab collaborates internationally, with recent publications spanning NO-based therapies, metabolic reprogramming in macrophages, and vascular biology.

• Cardiovascular Disease
• Nitric Oxide Signaling
• Redox Biology
• +۳ مورد دیگر

Prof. Hans Westerhoff is an Honorary Professor at the University of Amsterdam’s Division of Evolution, Infection and Genomics. His research focuses on systems biology, metabolic pathways, and cellular metabolism, with contributions to understanding inflammation, microbial ecosystems, and drug metabolism. He has published over 80 articles and holds the ISSB Fellowship (2014). His work integrates computational models with experimental data to address complex biological networks and their applications in medicine and environmental science. Research interests include metabolic control analysis, systems pharmacology, and microbial bioremediation. Notable projects involve studying neuronal differentiation dynamics, arsenic contamination mechanisms, and metabolic reprogramming in cancer cells. Supervised 18 students, fostering interdisciplinary approaches to systems biology challenges. Awards & Recognition: Fellow of the International Society for Systems Biology (2014) Collaborations span diverse fields: from neurodegenerative disease modeling to environmental microbiology, emphasizing cross-disciplinary problem-solving.

• Metabolic Pathways
• Systems Biology
• Biochemistry
• +۴ مورد دیگر

Dr. Michael Drozd is an Academic Clinical Lecturer in the School of Medicine at the University of Leeds, part of the Faculty of Medicine and Health. He is affiliated with the Leeds Institute of Cardiovascular and Metabolic Medicine, where he conducts translational research in cardiology with a focus on cardiometabolic diseases and infection. His work bridges clinical practice and scientific investigation, particularly in understanding how metabolic conditions like diabetes influence cardiovascular and infectious disease outcomes. Position: Academic Clinical Lecturer Institution: University of Leeds School: School of Medicine Research Institute: Leeds Institute of Cardiovascular and Metabolic Medicine Email: M.Drozd@leeds.ac.uk Dr. Drozd holds a BSc, MBChB (with honors), and PhD. He is a member of the Royal College of Physicians (MRCP) and the European Society of Cardiology (FESC), reflecting his clinical and academic credentials. His research interests center on cardiometabolic disease and infection , with a strong emphasis on translational approaches. Key areas include: Mechanisms linking diabetes, obesity, and cardiovascular disease Infection-related mortality in metabolic disorders Endothelial signaling in vascular dysfunction Biomarker discovery in heart failure Hypoxia and innate immune training Inflammation as a driver of cardiovascular risk His recent publications, spanning from 2017 to 2025, demonstrate a consistent output in high-impact journals such as Diabetes Care , Cardiovascular Research , The Lancet , and J Infect . These works often utilize large cohort data (e.g., UK Biobank) and molecular techniques to explore causal relationships and novel pathways. A recurring theme is the intersection of metabolic health, immune response, and cardiovascular outcomes. Dr. Drozd is actively involved in medical education, supervising MBChB students and academic foundation doctors, and delivering cardiovascular teaching across multiple years of the medical curriculum. He is also passionate about widening participation in medicine, contributing to equity in medical education. His scientific contributions include: Investigating plasma MERTK as a causal biomarker for infection mortality Identifying novel transcriptomic biomarkers (Erbb3, Hspa2) in diabetic heart failure Elucidating IGF-1 signaling in endothelial barrier function and atherogenesis Mapping comorbidity trajectories in heart failure Exploring mentorship challenges in cardiology training Dr. Drozd collaborates extensively with leading researchers such as Professor Mark T. Kearney, Dr. Ryan M. Cubbon, and Professor Stephen B. Wheatcroft. He is not listed as retired, deceased, or former staff, and there is no indication of part-time status. His ongoing research and teaching activities confirm his active role in academic medicine.

• Cardiology
• Cardiometabolic Disease
• Infection and Immunity
• +۷ مورد دیگر

Professor Stuart Rushworth is a faculty member at Norwich Medical School, University of East Anglia, where he serves as the scientific group leader for molecular haematology research. His work focuses on the tumour microenvironment in haematological malignancies, particularly Acute Myeloid Leukaemia and Multiple Myeloma, and the impact of infection and ageing on haematopoietic stem cells. Education: Bachelor's Degree – University of Sunderland PhD in Immunology – University of Cambridge Post-doctoral Training – University of Cambridge and University of East Anglia His research explores metabolic reprogramming, mitochondrial transfer, and stromal interactions in cancer. He has made significant contributions to understanding how leukaemia cells exploit the bone marrow microenvironment for survival and proliferation. His studies have identified key mechanisms such as fatty acid release from adipocytes and intercellular mitochondrial transfer via tunnelling nanotubes. His work bridges basic science and clinical translation, with implications for drug resistance and novel therapeutic strategies. The most recent articles highlight trends in immunometabolism, infection-induced haematopoietic stress responses, and metabolic crosstalk in cancer. Key themes include mitochondrial dynamics, metabolic adaptation, and innate immune signaling pathways like STING. His publications appear in high-impact journals such as Cell Reports , Nature Communications , and Blood . He is actively funded by major research bodies including the British Heart Foundation, The Big C Appeal, Academy of Medical Sciences, and BBSRC. While no formal scientific awards are listed in the provided text, his research has led to clinical trials involving BTK inhibitors in myeloma patients. Professor Rushworth mentors several PhD researchers, including Dominic Fowler-Shorten, E. E. Wojtowicz, A. Jibril, J. A. Moore, and J. Mistry. He leads the Rushworth Group, which is part of the Metabolic Health Research Centre at UEA, focusing on metabolic processes in the tumour microenvironment.

• Molecular Haematology
• Cancer Metabolism
• Tumour Microenvironment
• +۱۲ مورد دیگر

Lisa Heather is an Associate Professor and British Heart Foundation (BHF) Intermediate Fellow at the University of Oxford's Department of Physiology, Anatomy, and Genetics (DPAG) within the Medical Sciences Division. Her research focuses on cardiac metabolism in health and disease, particularly in diabetes and heart failure. She holds dual expertise in molecular mechanisms of metabolic dysfunction and translational cardiovascular research. Dr. Heather earned a Bachelor's degree in Medical Biochemistry from the University of Surrey and conducted doctoral research on cardiac hypertrophy's metabolic origins. Her postdoctoral work explored mitochondrial dysfunction in diabetic cardiomyopathy. Key career milestones include a Diabetes UK RD Lawrence Fellowship (2011) and a BHF Intermediate Fellowship (2018), supporting her investigations into lipid metabolism and hypoxia signaling in diabetic hearts. Her research interests span mitochondrial bioenergetics, fatty acid trafficking, hypoxia responses, and metabolic reprogramming in disease. She employs advanced techniques like hyperpolarized MRI and metabolomics to study real-time metabolic changes, with recent breakthroughs identifying novel roles for fatty acids in disrupting hypoxia signaling and cardiomyocyte function. Her publications (e.g., Diabetes , Physiological Reviews , JCI Insight ) highlight interdisciplinary approaches to metabolic disease. She leads the Heather Group, advancing therapies targeting metabolic pathways in heart failure and diabetes. Her work bridges basic science and clinical applications, emphasizing metabolic interventions for cardiovascular health.

• Cardiac Metabolism
• Diabetic Cardiomyopathy
• Mitochondrial Metabolism
• +۳ مورد دیگر

Dr. Ilaria Russo is a Lecturer in Bioscience at the Keele University School of Medicine. Her roles combine teaching and research in medical microbiology, pharmacology, and infectious diseases. She leads research on Plasmodium cell biology, malaria pathogenesis, and antimalarial drug targets. She holds an honorary Adjunct Professorship at Washington University in St. Louis, USA. Education: MSc in Pharmaceutical Chemistry (University of Padua), PhD in Cellular and Molecular Biology (University of Padua). Postdoctoral training at Washington University, supported by NIH and ERC grants. She has pioneered studies on Plasmodium's secretory pathways and validated novel drug targets such as calpain and plasmepsin V. Research Interests: Host-pathogen interactions, malaria parasite biology, vaccine development, and innovative in vitro models (e.g., BBB models, organoids). Her work bridges lab discoveries with field applications in the Democratic Republic of Congo (DRC), including diagnostic initiatives via the Fonte di Speranza Foundation. Key Achievements: Discovery of calpain and plasmepsin V as antimalarial targets, development of conditional knockdown techniques, and leadership in global health projects. Awards: ERC Reintegration Grant, Wellcome Trust Fellowship, and editorial roles in journals like Enliven: Immunology . Labs/Teams: Part of Keele's Centre for Applied Entomology and Parasitology (CAEP), collaborating with global networks including the Goldberg Lab (Washington University).

• Malaria Research
• Infectious Diseases
• Host-Pathogen Interactions
• +۳ مورد دیگر

Dr. Sumru Bayin leads a research group at the Cambridge Stem Cell Institute and is affiliated with the Gurdon Institute. She investigates molecular mechanisms governing neural stem cell behaviors and age-dependent regenerative capacity in the brain, focusing on neonatal cerebellar repair and adult brain regeneration limitations. PhD in Stem Cell Biology from NYU Langone School of Medicine Postdoctoral training at Memorial Sloan Kettering Cancer Centre Her research explores lineage plasticity in neural progenitors using genetically engineered mouse models, single-cell genomics, and injury models. Key projects address developmental signals for regeneration, adult stem cell characterization, and inhibitory mechanisms in mature brains. Her work has implications for autism spectrum disorder risk factors linked to cerebellar hypoplasia. Recent publications highlight cerebellar repair mechanisms (2021 Science Advances), Purkinje neuron regeneration (2018 eLife), and glioblastoma stem cell signaling pathways (2017 Oncotarget). Her lab's findings emphasize epigenetic silencing and developmental signal loss in adult regeneration failure. Wellcome Career Development Award (2023) NIH Pathway to Independence Award (K99/R00) Leading Edge Fellow (2020) Sloan Kettering Postdoctoral Award Dr. Bayin supervises PhD students Niamh Divers and Giada Vanacore, MPhil student Jens Bager Christensen, and collaborates with Research Associate Niamh Divers. Her lab's work spans developmental biology, regenerative medicine, and neuro-oncology applications.

• Neuroscience
• Stem Cell Biology
• Regenerative Medicine
• +۳ مورد دیگر

Professor Benedikt Kessler is a Full Professor of Biochemistry and Mass Spectrometry at the Target Discovery Institute within the Nuffield Department of Medicine at the University of Oxford. He leads a research group focused on the ubiquitin-proteasome system and deubiquitylating enzymes, with significant contributions to cancer research and neurodegenerative disease therapeutics. Professor Kessler received his B.A. in Biochemistry from the Swiss Federal Institute of Technology in 1992, followed by a Ph.D. in Immunology from the Ludwig Institute for Cancer Research. He completed post-doctoral training at Harvard Medical School under Hidde Ploegh before joining the University of Oxford in 2004 as a Research Group Leader. He established his independent research group in 2005 and relocated to the Target Discovery Institute in 2013. In 2014, he was promoted to Full Professor of Biochemistry & Life Science Mass Spectrometry. His research focuses on deubiquitylating enzymes (DUBs) and their role in cellular processes, with particular emphasis on cancer development and neurodegenerative disorders. Professor Kessler pioneered chemoproteomics methods to profile active ubiquitin processing enzymes and has made significant contributions to understanding how ubiquitin-based pathways can be targeted therapeutically. His laboratory developed ubiquitin-based active site directed probes that enabled profiling of active cellular DUB content, leading to discoveries about OTUB1 in infection and prostate cancer, USP4 and USP47 in DNA repair, and USP18 in immuno-oncology. His work has directly contributed to the development of novel inhibitors for DUBs including USP30 (for Parkinson's disease), USP28 (for squamous lung carcinoma), and USP7 (for multiple myeloma). Analysis of Professor Kessler's recent publications (2024-2025) reveals an expanding research portfolio with significant contributions across multiple domains: neurodegenerative disease therapeutics through hydrogen deuterium exchange mass spectrometry, kidney transplant immunology, ubiquitin pathway characterization in infectious diseases like malaria, and novel DUB inhibitor development. His work consistently bridges fundamental biochemistry with clinical applications, particularly in cancer therapeutics and neurodegenerative disorders, while increasingly incorporating advanced machine learning approaches for biomarker discovery. Scientific Awards and Recognition Cesar Roux Research Award of the Faculty of Medicine, Lausanne University Human Frontier Science Program Organization long-term fellowship Roche Research Foundation post-doctoral fellowship Multiple Myeloma Research Foundation Senior Research Award Wellcome Trust VIP Award (2005) MRC New Investigator Award (2006-2009) Professor Kessler's research has received substantial funding throughout his career, including the MRC New Investigator Award that supported his early independent work at Oxford. His contributions to understanding the ubiquitin-proteasome system led to translational applications, most notably contributing to the development of Velcade™ for multiple myeloma treatment. He is an active member of several prestigious scientific organizations including the British Mass Spectrometry Society, British Society of Cell Biology, and the American Association for Cancer Research. Professor Kessler serves as a NIH study section member and collaborates extensively through the DUB Alliance and Pfizer's Innovative Technology Enabling Network (ITEN). Professor Kessler leads the TDI Mass Spectrometry Laboratory at the Nuffield Department of Medicine, where his team develops advanced chemoproteomics methods to profile active ubiquitin processing enzymes. His laboratory maintains extensive collaborations across Oxford University including with the Oxford Ludwig Institute, Jenner Institute, Weatherall Institute of Molecular Medicine, and Structural Genomics Consortium. Internationally, he collaborates with researchers at Leiden University and maintains connections with the Harvard Medical School community where he began his academic career.

• Ubiquitin-Proteasome System
• Deubiquitylating Enzymes
• Proteomics
• +۷ مورد دیگر

Dr. Victor H Villar is a Research Fellow at the School of Medicine, University of St Andrews. He is affiliated with the Sir James Mackenzie Institute for Early Diagnosis and Cellular Medicine Division. His work focuses on cancer metabolism, biomarker discovery, and therapeutic strategies. Metabolism and Biomarkers Lab LC-MS-based metabolomics research His research interests include: Hepatocellular Carcinoma Soft Tissue Sarcoma Esophageal Cancer Tumor metabolism Cell signaling Autophagy Recent publications reveal trends in: Metastasis mechanisms Lipid metabolism in cancer Immunotherapy targets Metabolic pathway analysis Stromal-tumor interactions Physiological cell culture models Dr. Villar supervises postgraduate research students Mark Kelly and Keira Hughes, who are investigating biomarker discovery for hepatocellular carcinoma and sarcoma subtypes, respectively. The Metabolism and Biomarkers Lab employs LC-MS metabolomics to identify metabolic alterations in cancers.

• Cancer Metabolism
• Oncology
• LC-MS Metabolomics
• +۷ مورد دیگر

Professor Patrick Kennedy is a Clinical Professor of Translational Hepatology at the Faculty of Medicine and Dentistry , Queen Mary University of London (QMUL), and a Consultant Hepatologist at Barts Health NHS Trust. His research focuses on the translational aspects of Hepatitis B virus (HBV) infection, particularly in young adults, and he leads the dedicated young adult liver service at The Royal London Hospital. Research Themes : Redefining disease phases in Chronic Hepatitis B (CHB), age-related immune responses, treatment endpoints in CHB, and immune-mediated liver injury mechanisms. Collaborations : Works with national institutions like UCL, Imperial College London, and international partners such as Duke-NUS Medical School (Singapore) and University of Rome Tor Vergata (Italy). Teaching : Chairs the MSc in Gastroenterology program and contributes to undergraduate MBBS teaching, including bedside clinical instruction and virology modules.

• Viral Hepatitis
• Translational Hepatology
• Immunology
• +۹ مورد دیگر

Simon Moxon is an Associate Professor in Bioinformatics at the University of East Anglia (UEA), part of the School of Biological Sciences. His research focuses on applying next-generation sequencing (NGS) technologies to study biological problems, particularly small RNA bioinformatics and mechanisms of gene regulation at transcriptional and post-transcriptional levels. He has developed tools like miRCat2 and the UEA sRNA Workbench for miRNA detection and analysis. Notable collaborations include projects funded by the British Heart Foundation, NIH, and the Natural Environment Research Council, exploring topics such as chromatin landscapes, microRNA biogenesis, and epigenetic reprogramming. His work spans plant genomics, developmental biology, and molecular mechanisms in diseases like cancer. Recent publications highlight advancements in understanding miRNA regulation in plants and animals, epigenetic marks during zygotic reprogramming, and antimicrobial resistance in Bacillus species. Moxon actively mentors PhD students and contributes to editorial roles in journals like Frontiers in Molecular Biosciences.

• Bioinformatics
• Gene Regulation
• Next-Generation Sequencing
• +۳ مورد دیگر

Dr. Tatiana Novoselova serves as a Lecturer in Medical Sciences at the Institute of Health Sciences Education (IHSE) within Queen Mary University of London's Faculty of Medicine and Dentistry. She co-leads the Metabolism module for Phase 1 of the MBBS program and acts as Senior Internal Examiner for Year 2 Paper B, while teaching Metabolism and Brain and Behaviour modules across Year 1-2 MBBS and Graduate Entry Programme cohorts. Her educational background includes an MBBS from a top Russian medical school, followed by a PhD in Molecular and Cellular Neuroscience at University College London. This foundation supports her dual expertise in clinical education and laboratory research. Novoselova's research centers on molecular mechanisms of neurodegenerative disorders and ataxias, with significant contributions to understanding central metabolic regulation, obesity pathophysiology, and adrenal gland physiology. Her work bridges neuroscience and endocrinology through investigations of melanocortin receptor signaling, mitochondrial dysfunction in optic atrophy, and adrenal zonation defects. Analysis of her 15 most recent publications (2013-2022) reveals a consistent focus on genetic and molecular underpinnings of disease, utilizing iPSC models, multi-omic profiling, and animal studies. Key thematic clusters include optic atrophy mechanisms (OPA1-related), adrenal insufficiency genetics (MRAP/NNT pathways), and obesity-related neural circuits (melanocortin systems), demonstrating translational approaches from basic science to therapeutic strategies. No scientific awards, prizes, fellowships, or medals were documented in the source material. During her tenure at Middlesex University London, Novoselova supervised MSc and PhD students while leading the MSc Computational Neuroscience program. Current advising roles at Queen Mary include Senior Tutor and Academic Adviser for MBBS students, though specific grant funding details remain unreported. Her academic leadership extends to REF2021 contributions and ethics committee service. While collaborative research networks are evident through co-authored publications on adrenal physiology and neurodegeneration, explicit laboratory affiliations or dedicated research teams at Queen Mary were not specified in the available documentation.

• Neurodegenerative disorders
• Ataxias
• Metabolic regulation
• +۴ مورد دیگر

Dr Sevasti Zervou is a Stipendiary Lecturer in Cellular Biochemistry at St Peter’s College, University of Oxford, and Director of Studies for the MSc Precision Cancer Medicine program in the Department of Oncology. She holds a PhD in Molecular Medicine from the University of Warwick (2001) and has over 15 years of research experience in cardiovascular medicine, funded by the British Heart Foundation. Her academic roles include teaching undergraduate biochemistry, leading postgraduate modules in genetics for precision oncology, and mentoring junior researchers. Her research focuses on cellular metabolism, genetic regulation of heart function, and metabolic pathways in cardiovascular diseases, diabetes, and cancer. She has pioneered studies on creatine kinase systems, myocardial energetics, and therapeutic targets for heart failure. Beyond academia, she contributes to science outreach through guest lectures for sixth-form students and mentorship programs. Education: BSc (Hons) in Molecular Medicine (Warwick), PhD (Warwick), FHEA (Fellow of the Higher Education Academy). Research expertise includes molecular cloning, transcriptomics, proteomics, and high-throughput drug screening. She coordinates the MSc Precision Cancer Medicine program, overseeing academic content and teaching delivery. Her work integrates clinical research with educational innovation, emphasizing translational applications of cellular biochemistry. Her research portfolio includes over 30 peer-reviewed publications on topics like cardiac energetics, creatine metabolism, and nanomaterials for cardiovascular therapy. She collaborates with multidisciplinary teams in Oxford and has contributed to understanding metabolic inflexibility in heart disease. Teaching responsibilities span undergraduate tutorials in biochemistry (cell structure, metabolism, data analysis) and postgraduate modules in genetic oncology. She actively participates in academic governance as a Member of Congregation at St Peter’s College.

• Cellular Biochemistry
• Metabolism
• Genetics
• +۵ مورد دیگر

Professor Thuy Do holds the position of Professor of Molecular Microbiology at the University of Leeds School of Dentistry. She specializes in bacteriology, oral biofilms, and microbiome analysis using advanced sequencing technologies. Her research focuses on understanding oral microbiome dysbiosis, host-microbiome interactions, and developing diagnostic tools for systemic diseases linked to oral health. Education: She earned a Licence es Sciences from the Université de Strasbourg (1998), followed by BSc and MSc degrees from Teesside University (1999–2000) and a PhD in Bioprocess Development from De Montfort University (2004). She held a Postdoctoral Research Associate position at King’s College London before joining Leeds in 2012 as a Lecturer in Microbiology. Research Interests: Prof. Do’s work investigates oral microbiota diversity, functional biology of biofilms, and applications of metagenomics/RNA-Seq. Key projects include studying rheumatoid arthritis links to oral dysbiosis, root caries mechanisms, and developing microbiome-based therapies. She also explores antimicrobial materials and regenerative endodontics. Editorial & Leadership: She serves as Associate Editor for multiple journals including Oral Diseases and Frontiers in Oral Health. She chairs IADR committees on new investigator awards and science communication. Her work bridges dental microbiology with systemic health, emphasizing interdisciplinary collaboration. Advising & Training: Supervises postgraduate students in microbiology and dentistry. Teaches Microbiology modules to dental undergraduates. Active in mentoring early-career researchers through editorial roles and conference initiatives.

• Bacteriology
• Microbial Culturing Methods
• Oral Biofilms
• +۶ مورد دیگر

Dr. David Sumpton serves as an Honorary Senior Lecturer within the School of Cancer Sciences at the University of Glasgow, affiliated with the CRUK Scotland Institute in Glasgow. His research bridges cancer biology, metabolism, and therapeutic development, with particular focus on mitochondrial function in malignancies. His research interests center on cancer metabolism , especially mitochondrial pathways driving tumor progression and metastasis. Key areas include nucleotide metabolism (uridine phosphorylase), folate cycle regulation in leukemia, lipid signaling in metastatic niches, and immunometabolism interactions. His work demonstrates how metabolic rewiring enables immune evasion, metastatic colonization, and therapeutic resistance across prostate cancer, leukemia, and solid tumors. Analysis of his 2023-2025 publications reveals strong emphasis on metabolic vulnerabilities for therapeutic targeting, including drug repurposing (lomerizine for CML), mitochondrial DNA mutations enhancing immunotherapy response, and nutrient transporter dependencies (SLC7A5). His team frequently employs multi-omics approaches to stratify cancer subtypes and identify biomarker-driven treatments. While no formal advising or grant information is publicly documented, his collaborative publications across Nature journals, Science Translational Medicine, and Cell Biology indicate extensive institutional partnerships. His lab appears focused on translating metabolic discoveries into preclinical therapeutic strategies, particularly for treatment-resistant cancers. Dr. Sumpton maintains active research in tumor microenvironment dynamics, with recent work on extracellular vesicle-mediated metastatic niche formation and senescence-induced multi-organ dysfunction. His team utilizes physiological cell culture models to improve metabolic fidelity in cancer research.

• Cancer Metabolism
• Mitochondrial Biology
• Leukemia Research
• +۳ مورد دیگر